Feedback PLC Director/PDMR Shareholding: Correction (6554K)
22 December 2022 - 11:08PM
UK Regulatory
TIDMFDBK
RNS Number : 6554K
Feedback PLC
22 December 2022
Feedback plc
Director Dealings
Further to announcement 5307K, made on 22 December 2022 at
07:00, outlining Director Dealings, the Company notes that, due to
a clerical error, the shares were described as being "subscribed
for" rather than "purchased" and the nominal value was given as
"0.50 pence", not "GBP0.50". These were "Ordinary Shares" and not
"New Ordinary Shares". There have been no other amends than
clarification of purchasing of existing ordinary shares and amended
nominal value.
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the
frontline clinical technology company, announces the following
Directors' dealings:
Rory Shaw, Non Executive Chairman, has purchased 22,270 Ordinary
Shares at a price of 89.8 pence per Ordinary Share.
Philipp Prince, Non Executive Director, has purchased 4,531
Ordinary Shares at a price of 89.9 pence per Ordinary Share.
Annemijn Eschauzier, Non Executive Director, has purchased 5,440
Ordinary Shares at a price of 91.9 pence per Ordinary Share.
Details of the Ordinary Shares held by these Directors are
detailed in the table below:
Director/ Position Existing Ordinary Total beneficial Total interest
PDMR interest in Shares purchased interest in in Company's
Ordinary Shares Ordinary Shares issued share
capital
Non-Executive
Rory Shaw Chairman 56,303 22,270 78,573 0.59%
--------------- ------------------- -------------------- ------------------- -----------------
Philipp Non-Executive
Prince Director 20,232 4,531 24,763 0.19%
--------------- ------------------- -------------------- ------------------- -----------------
Annemijn Non-Executive
Eschauzier Director - 5,440 5,440 0.04%
--------------- ------------------- -------------------- ------------------- -----------------
The notification set out below, provides further details of such
dealings:
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Names Rory Shaw
Philipp Prince
Annemijn Eschauzier
--------------------------------------- -------------------------------------------------
Reason for the notification
2
------------------------------------------------------------------------------------------
a) Position/status Non-Executive Chairman
Non-Executive Director
Non-Executive Director
--------------------------------------- -------------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- -------------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------
a) Name Feedback plc
--------------------------------------- -------------------------------------------------
b) LEI 213800UGOF2GT2U2RV90
--------------------------------------- -------------------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of GBP0.50 each in Feedback
financial instrument, plc
type of instrument
Identification code GB00BJN59X09
b) Nature of the transaction Purchase of Ordinary Shares
--------------------------------------- -------------------------------------------------
c) Price(s) and volume(s)
---------------------- ----------------------
Price(s) Volume(s)
---------------------- ----------------------
89.8p 22,270
---------------------- ----------------------
89.9p 4,531
---------------------- ----------------------
91.9p 5,440
---------------------- ----------------------
d) Aggregated information
- Aggregated volume n/a
- Price
e) Date of the transaction 21 December 2022
--------------------------------------- -------------------------------------------------
f) Place of the transaction XLON
--------------------------------------- -------------------------------------------------
Enquiries:
Feedback plc +44 (0) 20 3997 7634
Tom Oakley, CEO IR@fbk.com
Anesh Patel, CFO
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Emma Earl/Freddy Crossley (Corporate
Finance)
Rupert Dearden (Corporate Broking) +44 (0)20 7886 2500
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Nick Rome/Joe Walker 07748 325 236 or 07407 020 470
About Feedback
Feedback plc helps clinical teams to make better decisions
faster for patients. We design products that enhance clinician
access to patient data and to their colleagues. Our unique approach
centres around individual patient episodes, into which we pull
relevant clinical data from hospital systems and around which we
build remote clinical teams for collaboration. As a result, we
produce a digital infrastructure that makes patient data available
to clinicians in multiple settings, in a format that enables them
to meaningfully interact with it, providing flexibility to
clinicians and free movement of patients between provider settings
- clinicians can practice from anywhere and patients can attend any
care provider for treatment.
Our products Bleepa and CareLocker work together to deliver
unparalleled value to our customers. Bleepa is our application
layer and sits on top of CareLocker as our data layer. Bleepa is a
clinician facing platform that displays clinical results from a
patient's CareLocker at a certified and regulated quality, that is
suitable for clinical use and enables dialogue on a
patient-by-patient basis with colleagues through a secure,
auditable chat interface that links back to the patient medical
record. The CareLocker data storage model is built around the
patient. Our vision is one where relevant clinical data is always
available to the patient as well as to any care setting that they
may attend - a federated data architecture with the patient as the
tenant.
The Company has a number of growth opportunities domestically
and internationally across a range of markets including the NHS,
the veterinary market and private healthcare providers and its
highly scalable Software as a Service ("SaaS")-based revenue model
is expected to provide increasing levels of visibility as the
Company grows its customer base.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHTTBTTMTMTBFT
(END) Dow Jones Newswires
December 22, 2022 07:08 ET (12:08 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2024 to Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2023 to Jul 2024